Peptide Database

86 therapeutic peptides with research summaries, clinical findings, and regulatory status.

Showing 11 peptides with status InvestigationalClear filters
MetabolicInvestigational

AOD-9604

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.

Subcutaneous injection, Oral
HormoneInvestigational

GHRP-2

A synthetic hexapeptide growth hormone secretagogue that acts on the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary to stimulate growth hormone release. GHRP-2 is one of the most potent GH-releasing peptides, producing robust GH pulses while also increasing ACTH, cortisol, and prolactin to a modest degree. It amplifies the natural GH axis and works synergistically with GHRH analogs.

Subcutaneous injection, Intravenous
HormoneInvestigational

GHRP-6

A synthetic hexapeptide growth hormone secretagogue that stimulates the anterior pituitary via GHS-R1a receptor activation. GHRP-6 produces significant GH release and also potently stimulates appetite through ghrelin-mimetic activity in hypothalamic feeding centers. It increases gastric motility and has cytoprotective effects on gastric and cardiac tissue through NO-mediated pathways.

Subcutaneous injection, Intravenous
HormoneInvestigational

Hexarelin

A synthetic hexapeptide growth hormone secretagogue with the highest GH-releasing potency among GHRPs. Hexarelin binds both GHS-R1a and CD36 (scavenger receptor), giving it unique cardiovascular properties independent of GH release. It exhibits cardioprotective effects through reduced atherosclerotic plaque formation and improved cardiac contractility via direct myocardial receptor activation.

Subcutaneous injection, Intravenous
ReproductiveInvestigational

Atosiban

A competitive oxytocin/vasopressin V1a receptor antagonist used as a tocolytic agent to delay preterm labor. Atosiban blocks oxytocin-mediated myometrial contractions without the cardiovascular side effects associated with beta-adrenergic tocolytics. The peptide is administered as an initial bolus followed by a step-down infusion protocol over up to 48 hours.

Intravenous
CognitiveInvestigational

Selank

A synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stability. Selank exhibits anxiolytic activity comparable to benzodiazepines without sedation, dependence, or withdrawal effects. It modulates the expression of BDNF, serotonin, dopamine, and norepinephrine, and influences IL-6 and GABA receptor expression.

Intranasal
CognitiveInvestigational

Cerebrolysin

A porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors. Cerebrolysin exhibits neurotrophic activity similar to BDNF, GDNF, and CNTF, promoting neuronal survival, synaptic plasticity, and neurogenesis. It modulates GSK-3beta, CDK5, and calcineurin-NFAT signaling cascades involved in neurodegeneration.

Intravenous, Intramuscular injection
ImmuneInvestigational

Thymalin

A peptide bioregulator originally extracted from bovine thymus gland, consisting of a mixture of polypeptides that modulate immune function. Thymalin restores T-cell mediated immunity by promoting T-lymphocyte maturation and differentiation in the thymus. It also normalizes the ratio of T-helper to T-suppressor cells and enhances phagocytic activity of neutrophils and macrophages.

Intramuscular injection
ImmuneInvestigational

VIP (Vasoactive Intestinal Peptide)

A 28-amino acid neuropeptide widely distributed in the central and peripheral nervous systems and immune cells. VIP acts through VPAC1 and VPAC2 receptors to produce potent anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) and promoting regulatory T-cell differentiation. It also functions as a vasodilator, bronchodilator, and neuromodulator.

Intranasal, Intravenous, Subcutaneous injection
ImmuneInvestigational

Thymosin Alpha 1 (Zadaxin)

A 28-amino acid peptide originally isolated from thymic tissue (thymosin fraction 5) that serves as a potent immunomodulator. Thymosin alpha 1 enhances T-cell maturation, dendritic cell function, and antibody responses by activating Toll-like receptors (TLR2, TLR9) on innate immune cells. It promotes Th1 immune responses and augments vaccine efficacy while modulating inflammatory cytokine production.

Subcutaneous injection
ImmuneInvestigational

Thymopentin (TP-5)

A synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr) corresponding to residues 32-36 of thymopoietin, a thymic hormone involved in T-cell differentiation. Thymopentin stimulates early T-cell precursor differentiation and modulates mature T-cell function by enhancing IL-2 production and expression of T-cell surface markers. It partially restores immune function in immunocompromised states without the risks of whole thymic extracts.

Subcutaneous injection, Intramuscular injection